{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:22:13Z","timestamp":1790666533043,"version":"4.1.0"},"reference-count":185,"publisher":"National Institute for Health and Care Research","issue":"83","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["14\/69\/03"],"award-info":[{"award-number":["14\/69\/03"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background and objectives<\/jats:title>\n \n Systematic reviews and economic modelling of clinical effectiveness and cost-effectiveness of therapeutic monitoring of tumour necrosis factor alpha (TNF-\u03b1) inhibitors [using LISA-TRACKER\n \u00ae<\/jats:sup>\n enzyme-linked immunosorbent assay (ELISA) kits (Theradiag, Marne La Vallee, France, or Alpha Laboratories, Heriot, UK), TNF-\u03b1-Blocker ELISA kits (Immundiagnostik AG, Bensheim, Germany) and Promonitor\n \u00ae<\/jats:sup>\n ELISA kits (Proteomika, Progenika Biopharma, Bizkaia, Spain)] versus standard care for Crohn\u2019s disease (CD).\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Multiple electronic databases were searched from inception to December 2014 in order to identify primary studies and meta-analyses.<\/jats:p>\n <\/jats:sec>\n \n Population<\/jats:title>\n \n Patients with moderate to severe active CD treated with infliximab (IFX) (Remicade\n \u00ae<\/jats:sup>\n , Merck Sharp & Dohme Ltd, Kenilworth, NJ, USA) or adalimumab (ADA) (Humira\n \u00ae<\/jats:sup>\n , AbbVie Inc., North Chicago, IL, USA).\n <\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Monitoring of serum anti-TNF-\u03b1 (IFX or ADA) and\/or of anti-drug antibody levels using test assays with a test\u2013treatment algorithm.<\/jats:p>\n <\/jats:sec>\n \n Comparator<\/jats:title>\n Standard care.<\/jats:p>\n <\/jats:sec>\n \n Outcomes<\/jats:title>\n Any patient-related outcome, test agreement and cost-effectiveness estimates. The quality assessments used recognised checklists (Quality Assessment of Diagnostic Accuracy Studies-2, Cochrane, Philips and Consolidated Health Economic Evaluation Reporting Standards). Evidence was synthesised using narrative review and meta-analysis. A Markov model was built in TreeAge Pro 2013 (TreeAge Software, Inc., Williamstown, MA, USA). The model had a 4-week cycle and a 10-year time horizon, adopted a NHS and Personal Social Services perspective and used a linked evidence approach. Costs were adjusted to 2013\/14 prices and discounted at 3.5%.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n We included 68 out of 2434 and 4 out of 2466 studies for the clinical effectiveness and cost-effectiveness reviews, respectively. Twenty-three studies comparing test methods were identified. Evidence on test concordance was sparse and contradictory, offering scant data for a linked evidence approach. Three studies [two randomised controlled trials (RCTs) and one retrospective observational study] investigated outcomes following implementation of a test algorithm. None used the specified commercial ELISA immunoassay test kits. Neither of the two RCTs demonstrated clinical benefit of a test\u2013treatment regimen. A meta-analysis of 31 studies to estimate test accuracy for predicting clinical status indicated that 20\u201330% of test results are likely to be inaccurate. The four cost-effectiveness studies suggested that testing results in small cost reductions. In the economic analysis the base-case analysis showed that standard practice (no testing\/therapeutic monitoring with the intervention tests) was more costly and more effective than testing for IFX. Sensitivity and scenario analyses gave similar results. The probabilistic sensitivity analysis indicated a 92% likelihood that the \u2018no-testing\u2019 strategy was cost-effective at a willingness to pay of \u00a320,000 per quality-adjusted life-year.<\/jats:p>\n <\/jats:sec>\n \n Strengths and limitations<\/jats:title>\n Rigorous systematic reviews were undertaken; however, the underlying evidence base was poor or lacking. There was uncertainty about a linked evidence approach and a lack of gold standard for assay comparison. The only comparative evidence available for economic evaluation was for assays other than the intervention assays.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Our finding that testing is not cost-effective for IFX should be viewed cautiously in view of the limited evidence. Clinicians should be mindful of variation in performance of different assays and of the absence of standardised approaches to patient assessment and treatment algorithms.<\/jats:p>\n <\/jats:sec>\n \n Future work recommendations<\/jats:title>\n There is substantial variation in the underlying treatment pathways and uncertainty in the relative effectiveness of assay- and test-based treatment algorithms, which requires further investigation. There is very little research evidence on ADA or on drug monitoring in children with CD, and conclusions on cost-effectiveness could not be reached for these.<\/jats:p>\n <\/jats:sec>\n \n Study registration<\/jats:title>\n This study is registered as PROSPERO CRD42014015278.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n The National Institute for Health Research Health Technology Assessment programme.<\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/hta20830","type":"journal-article","created":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T06:57:14Z","timestamp":1479193034000},"page":"1-288","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":33,"title":["Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-\u03b1) inhibitors [LISA-TRACKER\u00ae enzyme-linked immunosorbent assay (ELISA) kits, TNF-\u03b1-Blocker ELISA kits and Promonitor\u00ae ELISA kits] versus standard care in patients with Crohn\u2019s disease: systematic reviews and economic modelling"],"prefix":"10.3310","volume":"20","author":[{"given":"Karoline","family":"Freeman","sequence":"first","affiliation":[{"name":"Warwick Evidence, Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Connock","sequence":"additional","affiliation":[{"name":"Warwick Evidence, Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Auguste","sequence":"additional","affiliation":[{"name":"Warwick Evidence, Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sian","family":"Taylor-Phillips","sequence":"additional","affiliation":[{"name":"Warwick Evidence, Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hema","family":"Mistry","sequence":"additional","affiliation":[{"name":"Warwick Evidence, Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepson","family":"Shyangdan","sequence":"additional","affiliation":[{"name":"Warwick Evidence, Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Court","sequence":"additional","affiliation":[{"name":"Warwick Evidence, Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Arasaradnam","sequence":"additional","affiliation":[{"name":"Clinical Sciences Research Institute, University of Warwick, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sutcliffe","sequence":"additional","affiliation":[{"name":"Warwick Evidence, Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen","family":"Clarke","sequence":"additional","affiliation":[{"name":"Warwick Evidence, Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2016,11]]},"reference":[{"key":"key20161111091621264_ref1-bib1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1017\/S0266462313000287","article-title":"The \u2018linked evidence approach\u2019 to assess medical tests: a critical analysis","volume":"29","author":"Merlin","year":"2013","journal-title":"Int J Technol Assess Health Care"},{"key":"key20161111091621264_ref1-bib2","volume-title":"Crohn\u2019s Disease: Management in Adults, Children and Young People","author":"NICE","year":"2012"},{"issue":"3","key":"key20161111091621264_ref1-bib3","doi-asserted-by":"publisher","DOI":"10.3310\/hta7030","article-title":"Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn\u2019s disease","volume":"7","author":"Clark","year":"2003","journal-title":"Health Technol Assess"},{"key":"key20161111091621264_ref1-bib4","volume-title":"Crohn\u2019s Disease","author":"NHS Choices","year":"2013"},{"issue":"6","key":"key20161111091621264_ref1-bib5","doi-asserted-by":"publisher","DOI":"10.3310\/hta15060","article-title":"A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-\u03b1) inhibitors, adalimumab and infliximab, for Crohn\u2019s disease","volume":"15","author":"Dretzke","year":"2011","journal-title":"Health Technol Assess"},{"key":"key20161111091621264_ref1-bib6","volume-title":"Infliximab (Review) and Adalimumab for the Treatment of Crohn\u2019s Disease","author":"NICE","year":"2010"},{"key":"key20161111091621264_ref1-bib7","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1111\/j.1572-0241.2001.03671.x","article-title":"Management of Crohn\u2019s disease in adults","volume":"96","author":"Hanauer","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"key20161111091621264_ref1-bib8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1136\/adc.85.5.435","article-title":"Inflammatory bowel disease","volume":"85","author":"Jenkins","year":"2001","journal-title":"Arch Dis Child"},{"key":"key20161111091621264_ref1-bib9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1046\/j.1365-2036.17.s2.17.x","article-title":"Review article: Crohn\u2019s disease: monitoring disease activity","volume":"17","author":"Sostegni","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"key20161111091621264_ref1-bib10","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","article-title":"Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn\u2019s disease in children","volume":"132","author":"Hyams","year":"2007","journal-title":"Gastroenterology"},{"key":"key20161111091621264_ref1-bib11","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1136\/gut.2005.069476","article-title":"Laboratory markers in IBD: useful, magic, or unnecessary toys?","volume":"55","author":"Vermeire","year":"2006","journal-title":"Gut"},{"key":"key20161111091621264_ref1-bib12","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1053\/gast.2002.31072","article-title":"A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn\u2019s disease","volume":"122","author":"Sandborn","year":"2002","journal-title":"Gastroenterology"},{"key":"key20161111091621264_ref1-bib13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/00004836-199501000-00008","article-title":"Usual therapy improves perianal Crohn\u2019s disease as measured by a new disease activity index. McMaster IBD Study Group","volume":"20","author":"Irvine","year":"1995","journal-title":"J Clin Gastroenterol"},{"key":"key20161111091621264_ref1-bib14","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.crohns.2010.04.004","article-title":"Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects","volume":"4","author":"Allez","year":"2010","journal-title":"J Crohns Colitis"},{"key":"key20161111091621264_ref1-bib15","volume-title":"Crohn\u2019s Disease: Tests for Therapeutic Monitoring of TNF Inhibitors (LISA-TRACKER ELISA kits, TNF\u03b1-Blocker ELISA kits, and Promonitor ELISA kits): Final Protocol","author":"Freeman","year":"2014"},{"key":"key20161111091621264_ref1-bib16","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/ajg.2008.168","article-title":"Management of Crohn\u2019s disease in adults","volume":"104","author":"Lichtenstein","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"key20161111091621264_ref1-bib17","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","article-title":"The second European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease: current management","volume":"4","author":"Dignass","year":"2010","journal-title":"J Crohns Colitis"},{"key":"key20161111091621264_ref1-bib18","volume-title":"British National Formulary","author":"Joint Formulary Committee"},{"key":"key20161111091621264_ref1-bib19","volume-title":"British National Formulary for Children","author":"Joint Formulary Committee"},{"key":"key20161111091621264_ref1-bib20","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/ibd.3780030405","article-title":"An evaluation of utility measurement in Crohn\u2019s disease","volume":"3","author":"Gregor","year":"1997","journal-title":"Inflamm Bowel Dis"},{"key":"key20161111091621264_ref1-bib21","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1046\/j.1365-2036.2002.01323.x","article-title":"The quality of life in patients with Crohn\u2019s disease","volume":"16","author":"Cohen","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"key20161111091621264_ref1-bib22","volume-title":"Standards for the Healthcare of People who have Inflammatory Bowel Disease (IBD): 2013 Update","author":"IBD Standards Group","year":"2013"},{"key":"key20161111091621264_ref1-bib23","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1136\/gut.2004.041616","article-title":"Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study","volume":"53","author":"Bassi","year":"2004","journal-title":"Gut"},{"key":"key20161111091621264_ref1-bib24","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1097\/00042737-200510000-00007","article-title":"Infliximab use in Crohn\u2019s disease: impact on health care resources in the UK","volume":"17","author":"Jewell","year":"2005","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"key20161111091621264_ref1-bib25","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/j.1365-2036.2010.04482.x","article-title":"Costs of care for Crohn\u2019s disease following the introduction of infliximab: a single-centre UK experience","volume":"32","author":"Sprakes","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"key20161111091621264_ref1-bib26","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.crohns.2011.02.005","article-title":"Managing the long term care of inflammatory bowel disease patients: the cost to European health care providers","volume":"5","author":"Buchanan","year":"2011","journal-title":"J Crohns Colitis"},{"key":"key20161111091621264_ref1-bib27","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"key20161111091621264_ref1-bib28","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/S1542-3565(04)00414-8","article-title":"Long-term treatment of rectovaginal fistulas in Crohn\u2019s disease: response to infliximab in the ACCENT II Study","volume":"2","author":"Sands","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key20161111091621264_ref1-bib29","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"key20161111091621264_ref1-bib30","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nrgastro.2013.253","article-title":"Tailoring anti-TNF therapy in IBD: drug levels and disease activity","volume":"11","author":"Ben-Horin","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"key20161111091621264_ref1-bib31","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"key20161111091621264_ref1-bib32","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"key20161111091621264_ref1-bib33","first-page":"83","article-title":"Management of Crohn\u2019s disease in poor responders to adalimumab","volume":"7","author":"de Boer","year":"2014","journal-title":"Clin Exp Gastroenterol"},{"key":"key20161111091621264_ref1-bib34","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.2217\/imt.12.114","article-title":"Anti-TNF-alpha biotherapies: perspectives for evidence-based personalized medicine","volume":"4","author":"Bendtzen","year":"2012","journal-title":"Immunotherapy"},{"key":"key20161111091621264_ref1-bib35","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/ajg.2008.88","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn\u2019s disease: a review","volume":"104","author":"Gisbert","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"key20161111091621264_ref1-bib36","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/ajg.2011.60","article-title":"Loss of response and need for adalimumab dose intensification in Crohn\u2019s disease: a systematic review","volume":"106","author":"Billioud","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"key20161111091621264_ref1-bib37","doi-asserted-by":"publisher","first-page":"S-196","DOI":"10.1016\/S0016-5085(14)60690-9","article-title":"Adalimumab or infliximab for the treatment of inflammatory bowel disease patients: which is more effective?","volume":"146","author":"Carrillo-Ramos","year":"2014","journal-title":"Gastroenterology"},{"key":"key20161111091621264_ref1-bib38","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","article-title":"Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn\u2019s disease","volume":"4","author":"Maser","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key20161111091621264_ref1-bib39","first-page":"11","article-title":"Why don\u2019t we just measure infliximab drug levels in IBD?","volume":"34","author":"Cassinotti","year":"2010","journal-title":"Pract Gastroenterol"},{"key":"key20161111091621264_ref1-bib40","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/S1542-3565(04)00238-1","article-title":"Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn\u2019s disease","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key20161111091621264_ref1-bib41","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/S1873-9946(14)60087-8","article-title":"Predictors of formation of antibodies to infliximab (ATI) and secondary loss of response in IBD patients treated with infliximab","volume":"8","author":"Ungar","year":"2014","journal-title":"J Crohns Colitis"},{"key":"key20161111091621264_ref1-bib42","doi-asserted-by":"publisher","first-page":"S-387","DOI":"10.1016\/s0016-5085(12)61466-8","article-title":"The prevalence of human antichimeric antibodies in patients on infliximab increases with age","volume":"142","author":"Barry","year":"2012","journal-title":"Gastroenterology"},{"key":"key20161111091621264_ref1-bib43","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"key20161111091621264_ref1-bib44","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/apt.12407","article-title":"Review article: a clinician\u2019s guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease","volume":"38","author":"Khanna","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"key20161111091621264_ref1-bib45","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn\u2019s disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"},{"key":"key20161111091621264_ref1-bib46","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.1016\/S1873-9946(12)60273-6","article-title":"Transient versus sustained antibodies to infliximab: possibility to overcome low titer antibody responses by dose optimisation","volume":"6","author":"Vande Casteele","year":"2012","journal-title":"J Crohns Colitis"},{"key":"key20161111091621264_ref1-bib47","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/j.1572-0241.2007.01638.x","article-title":"Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn\u2019s disease","volume":"103","author":"Ainsworth","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"key20161111091621264_ref1-bib48","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1053\/j.gastro.2009.07.062","article-title":"Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn\u2019s disease","volume":"137","author":"Karmiris","year":"2009","journal-title":"Gastroenterology"},{"key":"key20161111091621264_ref1-bib49","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1136\/annrheumdis-2012-202220","article-title":"The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis","volume":"72","author":"Garces","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20161111091621264_ref1-bib50","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1097\/FTD.0000000000000074","article-title":"Development of a universal anti-adalimumab antibody standard for interlaboratory harmonization","volume":"36","author":"Gils","year":"2014","journal-title":"Ther Drug Monit"},{"key":"key20161111091621264_ref1-bib51","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/annrheumdis-2014-206237","article-title":"The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region","volume":"74","author":"van Schie","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key20161111091621264_ref1-bib52","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1111\/apt.12330","article-title":"Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease","volume":"37","author":"Steenholdt","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"key20161111091621264_ref1-bib53","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1053\/j.gastro.2008.03.004","article-title":"Withdrawal of immunosuppression in Crohn\u2019s disease treated with scheduled infliximab maintenance: a randomized trial","volume":"134","author":"Van Assche","year":"2008","journal-title":"Gastroenterology"},{"key":"key20161111091621264_ref1-bib54","doi-asserted-by":"publisher","first-page":"S167","DOI":"10.1016\/S0016-5085(10)60767-6","article-title":"Methotrexate for the prevention of antibodies to infliximab in patients with Crohn\u2019s disease","volume":"138","author":"Feagan","year":"2010","journal-title":"Gastroenterology"},{"key":"key20161111091621264_ref1-bib55","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"key20161111091621264_ref1-bib56","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/ajg.2010.9","article-title":"Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease","volume":"105","author":"Afif","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"key20161111091621264_ref1-bib57","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/ajg.2014.146","article-title":"Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases","volume":"109","author":"Roblin","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"key20161111091621264_ref1-bib58","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1097\/MIB.0b013e3182a77b41","article-title":"Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study","volume":"19","author":"Paul","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"key20161111091621264_ref1-bib59","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1002\/ibd.21839","article-title":"Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease","volume":"18","author":"Pariente","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"key20161111091621264_ref1-bib60","first-page":"B4616","article-title":"Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn\u2019s disease","volume":"60","author":"Steenholdt","year":"2013","journal-title":"Dan Med J"},{"key":"key20161111091621264_ref1-bib61","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: loss of response to anti-TNF treatments in Crohn\u2019s disease","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"key20161111091621264_ref1-bib62","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/ibd.20899","article-title":"Incidence and clinical significance of immunogenicity to infliximab in Crohn\u2019s disease: a critical systematic review","volume":"15","author":"Cassinotti","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"key20161111091621264_ref1-bib63","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1097\/MEG.0b013e32835558cf","article-title":"Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis","volume":"24","author":"Lee","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"key20161111091621264_ref1-bib64","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1111\/j.1365-2036.2012.05057.x","article-title":"Systematic review: antibodies and anti-TNF-alpha levels in inflammatory bowel disease","volume":"35","author":"Chaparro","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"key20161111091621264_ref1-bib65","first-page":"A1","article-title":"Randomised controlled trial of drug level versus clinically based dosing of infliximab maintenance therapy in IBD: final results of the TAXIT Study (OP001)","volume":"1","author":"Vande Casteele","year":"2013","journal-title":"United Europ Gastroenterol J"},{"key":"key20161111091621264_ref1-bib66","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11938-013-0004-5","article-title":"Therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease","volume":"12","author":"Scott","year":"2014","journal-title":"Curr Treat Options Gastroenterol"},{"key":"key20161111091621264_ref1-bib67","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/apt.12030","article-title":"Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays","volume":"36","author":"Vande Casteele","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"key20161111091621264_ref1-bib68","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"key20161111091621264_ref1-bib69","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"key20161111091621264_ref1-bib70","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"key20161111091621264_ref1-bib71","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/jech.52.6.377","article-title":"The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions","volume":"52","author":"Downs","year":"1998","journal-title":"J Epidemiol Community Health"},{"key":"key20161111091621264_ref1-bib72","volume-title":"Methods Guide for Medical Test Reviews","author":"Chang","year":"2012"},{"key":"key20161111091621264_ref1-bib73","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"},{"key":"key20161111091621264_ref1-bib74","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan\u2013Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"key20161111091621264_ref1-bib75","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/1536867X0900900203","article-title":"metandi: meta-analysis of diagnostic accuracy using hierarchical logistic regression","volume":"9","author":"Harbord","year":"2009","journal-title":"Stata J"},{"key":"key20161111091621264_ref1-bib76","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1536867X0800800102","article-title":"Metan: fixed- and random-effects meta-analysis","volume":"8","author":"Harris","year":"2008","journal-title":"Stata J"},{"key":"key20161111091621264_ref1-bib77","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/j.cgh.2014.01.033","article-title":"Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy","volume":"12","author":"Baert","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key20161111091621264_ref1-bib78","doi-asserted-by":"publisher","first-page":"S-775","DOI":"10.1016\/S0016-5085(13)62866-8","article-title":"Association of serum infliximab and antibodies to infliximab to long-term clinical outcome and mucosal healing in Crohn\u2019s disease","volume":"144","author":"Ben-Bassat","year":"2013","journal-title":"Gastroenterology"},{"key":"key20161111091621264_ref1-bib79","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1136\/gut.2009.201533","article-title":"The immunogenic part of infliximab is the F(ab\u2019)2, but measuring antibodies to the intact infliximab molecule is more clinically useful","volume":"60","author":"Ben-Horin","year":"2011","journal-title":"Gut"},{"key":"key20161111091621264_ref1-bib80","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/j.1365-2036.2012.04997.x","article-title":"The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD","volume":"35","author":"Ben-Horin","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"key20161111091621264_ref1-bib81","doi-asserted-by":"publisher","first-page":"S278","DOI":"10.1016\/S1873-9946(14)60625-5","article-title":"ELISA vs. HMSA: a comparison between two different methods for the evaluation of adalimumab serum concentration and anti-adalimumab antibodies preliminary data","volume":"8","author":"Bodini","year":"2014","journal-title":"J Crohns Colitis"},{"key":"key20161111091621264_ref1-bib82","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.crohns.2012.10.019","article-title":"Infliximab trough levels may predict sustained response to infliximab in patients with Crohn\u2019s disease","volume":"7","author":"Bortlik","year":"2013","journal-title":"J Crohns Colitis"},{"key":"key20161111091621264_ref1-bib83","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.clim.2005.07.010","article-title":"Clinical and biological consequences of immunization to infliximab in pediatric Crohn\u2019s disease","volume":"118","author":"Candon","year":"2006","journal-title":"Clin Immunol"},{"key":"key20161111091621264_ref1-bib84","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1097\/MIB.0b013e3182813242","article-title":"Serum adalimumab concentration and clinical remission in patients with Crohn\u2019s disease","volume":"19","author":"Chiu","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"key20161111091621264_ref1-bib85","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1136\/gutjnl-2012-304094","article-title":"Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial","volume":"63","author":"Cornillie","year":"2014","journal-title":"Gut"},{"key":"key20161111091621264_ref1-bib86","doi-asserted-by":"publisher","first-page":"7367","DOI":"10.1007\/s00216-013-7154-0","article-title":"A rapid assay for on-site monitoring of infliximab trough levels: a feasibility study","volume":"405","author":"Corstjens","year":"2013","journal-title":"Anal Bioanal Chem"},{"key":"key20161111091621264_ref1-bib87","doi-asserted-by":"publisher","first-page":"S213","DOI":"10.1016\/S1873-9946(13)60529-2","article-title":"Evaluation of the diagnostic performance of two commercially available tests for infliximab trough levels (IFX-TL) and antibodies to infliximab (ATI) titration in inflammatory bowel disease (IBD)","volume":"7","author":"Daperno","year":"2013","journal-title":"J Crohns Colitis"},{"key":"key20161111091621264_ref1-bib88","doi-asserted-by":"publisher","first-page":"S-430","DOI":"10.1016\/S0016-5085(13)61583-8","article-title":"Infliximab re-induction outcomes after a failure to treatment","volume":"144","author":"Dauer","year":"2013","journal-title":"Gastroenterol"},{"key":"key20161111091621264_ref1-bib89","doi-asserted-by":"crossref","first-page":"S548","DOI":"10.14309\/00000434-201310001-01817","article-title":"Homogenous mobility shift assay (HMSA) overcomes the limitations of ELISA and ECLIA assays for monitoring infliximab (IFX), adalimumab (ADA), and associated anti-drug antibodies in serum","volume":"108","author":"Egea-Pujol","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"key20161111091621264_ref1-bib90","doi-asserted-by":"publisher","first-page":"S-779","DOI":"10.1016\/S0016-5085(13)62880-2","article-title":"Comparison of early measurement of infliximab and antibodies-to-infliximab serum levels with standard trough analysis","volume":"144","author":"Eser","year":"2013","journal-title":"Gastroenterology"},{"key":"key20161111091621264_ref1-bib91","doi-asserted-by":"publisher","first-page":"S231","DOI":"10.1016\/S1873-9946(13)60572-3","article-title":"Detection of anti infliximab antibodies in patients with inflammatory bowel disease (IBD) in the presence of infliximab by homogeneous liquid phase anti infliximab mobility shift assay","volume":"7","author":"Eser","year":"2013","journal-title":"J Crohns Colitis"},{"key":"key20161111091621264_ref1-bib92","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1053\/gast.2003.50145","article-title":"Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn\u2019s disease: a randomized controlled trial","volume":"124","author":"Farrell","year":"2003","journal-title":"Gastroenterology"},{"key":"key20161111091621264_ref1-bib93","doi-asserted-by":"publisher","first-page":"S-114","DOI":"10.1016\/S0016-5085(12)60430-2","article-title":"Novel infliximab (IFX) and antibody-to-infliximab (ATI) assays are predictive of disease activity in patients with Crohn\u2019s disease (CD)","volume":"142","author":"Feagan","year":"2012","journal-title":"Gastroenterology"},{"key":"key20161111091621264_ref1-bib94","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1097\/MIB.0000000000000138","article-title":"Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD","volume":"20","author":"Frederiksen","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"key20161111091621264_ref1-bib95","doi-asserted-by":"publisher","first-page":"S223","DOI":"10.1016\/S1873-9946(14)60498-0","article-title":"Predictors of sub-therapeutic infliximab or adalimumab trough levels and anti-drug antibodies and their influence on therapeutic decisions","volume":"8","author":"Goldberg","year":"2014","journal-title":"J Crohns Colitis"},{"key":"key20161111091621264_ref1-bib96","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.1016\/S1873-9946(14)60208-7","article-title":"Development and validation of ELISA to measure serum anti TNFa levels","volume":"8","author":"Greathead","year":"2014","journal-title":"J Crohns Colitis"},{"key":"key20161111091621264_ref1-bib97","doi-asserted-by":"publisher","first-page":"S-538","DOI":"10.1016\/S0016-5085(12)62067-8","article-title":"Comparison of homogeneous mobility shift assay and solid phase elisa for the measurement of drug and anti-drug antibody (ADA) levels in serum from patients treated with anti-TNF biologics","volume":"142","author":"Hauenstein","year":"2012","journal-title":"Gastroenterology"},{"key":"key20161111091621264_ref1-bib98","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s00535-013-0807-0","article-title":"C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn\u2019s disease","volume":"49","author":"Hibi","year":"2014","journal-title":"J Gastroenterol"},{"key":"key20161111091621264_ref1-bib99","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s00535-011-0474-y","article-title":"Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease","volume":"47","author":"Imaeda","year":"2012","journal-title":"J Gastroenterol"},{"key":"key20161111091621264_ref1-bib100","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s00535-013-0803-4","article-title":"Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn\u2019s disease","volume":"49","author":"Imaeda","year":"2014","journal-title":"J Gastroenterol"},{"key":"key20161111091621264_ref1-bib101","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s00535-013-0829-7","article-title":"Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn\u2019s disease under scheduled maintenance treatment","volume":"49","author":"Imaeda","year":"2014","journal-title":"J Gastroenterol"},{"key":"key20161111091621264_ref1-bib102","first-page":"59","article-title":"Trough serum infliximab level, anti-infliximab antibody status and response to infliximab maintenance treatment in inflammatory bowel disease (IBD)","volume":"26","author":"Kong","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"key20161111091621264_ref1-bib103","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1002\/ibd.21919","article-title":"Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies","volume":"18","author":"Kopylov","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"key20161111091621264_ref1-bib104","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/apt.12733","article-title":"A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn\u2019s disease","volume":"39","author":"Levesque","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"key20161111091621264_ref1-bib105","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.crohns.2014.01.009","article-title":"Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment","volume":"8","author":"Marits","year":"2014","journal-title":"J Crohns Colitis"},{"key":"key20161111091621264_ref1-bib106","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1016\/S1590-8658(14)60224-3","article-title":"Role of trough levels and antibodies to infliximab in the evaluation of loss of response and infusion reactions to infliximab therapy in inflammatory bowel disease","volume":"46","author":"Marzo","year":"2014","journal-title":"Dig Liver Dis"},{"key":"key20161111091621264_ref1-bib107","doi-asserted-by":"publisher","first-page":"S-778","DOI":"10.1016\/S0016-5085(13)62874-7","article-title":"Evaluating adalimumab drug and antibody levels as predictors of clinical and laboratory response in Crohn\u2019s disease patients","volume":"144","author":"Mazor","year":"2013","journal-title":"Gastroenterology"},{"key":"key20161111091621264_ref1-bib108","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/apt.12869","article-title":"Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn\u2019s disease","volume":"40","author":"Mazor","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"key20161111091621264_ref1-bib109","doi-asserted-by":"crossref","first-page":"S527","DOI":"10.14309\/00000434-201310001-01745","article-title":"Clinical utility of next generation infliximab and antibodies to infliximab assay","volume":"108","author":"McTigue","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"key20161111091621264_ref1-bib110","doi-asserted-by":"publisher","first-page":"A99","DOI":"10.1136\/gutjnl-2015-309861.202","article-title":"Therapeutic cut-off of infliximab in patients with inflammatory bowel diseases","volume":"64","author":"Nagore","year":"2015","journal-title":"Gut"},{"key":"key20161111091621264_ref1-bib111","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/ajg.2012.363","article-title":"Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis","volume":"108","author":"Nanda","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"key20161111091621264_ref1-bib112","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.3748\/wjg.v20.i17.5031","article-title":"Utility of serum TNF-alpha, infliximab trough level, and antibody titers in inflammatory bowel disease","volume":"20","author":"Pallagi-Kunstar","year":"2014","journal-title":"World J Gastroenterol"},{"key":"key20161111091621264_ref1-bib113","doi-asserted-by":"publisher","first-page":"S354","DOI":"10.1016\/S0016-5085(12)61332-8","article-title":"Interest of the dosage of serum concentration of infliximab and antibodies anti infliximab in the therapeutic response under infliximab in IBD","volume":"142","author":"Paul","year":"2012","journal-title":"Gastroenterology"},{"key":"key20161111091621264_ref1-bib114","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1097\/MIB.0000000000000037","article-title":"Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis","volume":"20","author":"Paul","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"key20161111091621264_ref1-bib115","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cgh.2013.07.010","article-title":"Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases","volume":"12","author":"Roblin","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key20161111091621264_ref1-bib116","doi-asserted-by":"publisher","first-page":"e287","DOI":"10.1515\/cclm-2013-0461","article-title":"Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels","volume":"51","author":"Ruiz-Arguello","year":"2013","journal-title":"Clin Chem Lab Med"},{"key":"key20161111091621264_ref1-bib117","first-page":"19","article-title":"PA-G-0035 Comparison of different tests for determination of infliximab levels and antibodies against infliximab in pediatric IBD patients. The 46th Annual Meeting of The European Society of Paediatric Gastroenterology, Hepatology and Nutrition, London, 8\u201311 May 2013","volume":"56","author":"Schatz","year":"2013","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"key20161111091621264_ref1-bib118","first-page":"eA27","article-title":"Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease","volume":"51","author":"Semmler","year":"2013","journal-title":"Clin Chem Lab Med"},{"key":"key20161111091621264_ref1-bib119","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1097\/MIB.0000000000000137","article-title":"Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease","volume":"20","author":"Singh","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"key20161111091621264_ref1-bib120","doi-asserted-by":"publisher","first-page":"310","DOI":"10.3109\/00365521.2010.536254","article-title":"Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn\u2019s disease","volume":"46","author":"Steenholdt","year":"2011","journal-title":"Scand J Gastroenterol"},{"key":"key20161111091621264_ref1-bib121","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1097\/FTD.0b013e31828d23c3","article-title":"Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn\u2019s disease","volume":"35","author":"Steenholdt","year":"2013","journal-title":"Ther Drug Monit"},{"key":"key20161111091621264_ref1-bib122","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/ajg.2014.106","article-title":"Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn\u2019s disease: post hoc analysis of a randomized controlled trial","volume":"109","author":"Steenholdt","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"key20161111091621264_ref1-bib123","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1136\/gutjnl-2013-305279","article-title":"Individualised therapy is more cost-effective than dose intensification in patients with Crohn\u2019s disease who lose response to anti-TNF treatment: a randomised, controlled trial","volume":"63","author":"Steenholdt","year":"2014","journal-title":"Gut"},{"key":"key20161111091621264_ref1-bib124","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1007\/s10620-015-3581-4","article-title":"Individualized therapy is a long-term cost-effective method compared to dose intensification in Crohn\u2019s disease patients failing infliximab","volume":"60","author":"Steenholdt","year":"2015","journal-title":"Dig Dis Sci"},{"key":"key20161111091621264_ref1-bib125","doi-asserted-by":"publisher","first-page":"S-245","DOI":"10.1016\/S0016-5085(14)60862-3","article-title":"The clinical and immunological significance of low level of infliximab in the absence of anti-infliximab antibodies in patients with IBD","volume":"146","author":"Ungar","year":"2014","journal-title":"Gastroenterology"},{"key":"key20161111091621264_ref1-bib126","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ajg.2013.12","article-title":"Antibody response to infliximab and its impact on pharmacokinetics can be transient","volume":"108","author":"Vande Casteele","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"key20161111091621264_ref1-bib127","doi-asserted-by":"publisher","first-page":"S-242","DOI":"10.1016\/S0016-5085(14)60852-0","article-title":"TNF-responsive cellular based assay reveals neutralizing capacity of anti-adalimumab antibodies in Crohn\u2019s disease and ulcerative colitis patients","volume":"146","author":"Vande Casteele","year":"2014","journal-title":"Gastroenterology"},{"key":"key20161111091621264_ref1-bib128","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1097\/MIB.0000000000000156","article-title":"Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study","volume":"20","author":"Vaughn","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"key20161111091621264_ref1-bib129","doi-asserted-by":"publisher","first-page":"S684","DOI":"10.1016\/s0016-5085(10)63147-2","article-title":"Measurement of human anti-chimeric antibodies (HACA) and infliximab levels in patient serum using a novel homogeneous assay","volume":"138","author":"Wang","year":"2010","journal-title":"Gastroenterology"},{"key":"key20161111091621264_ref1-bib130","doi-asserted-by":"crossref","first-page":"S475","DOI":"10.14309\/00000434-201110002-01254","article-title":"Evaluation of a novel homogeneous mobility shift assay for the measurement of human antibodies-to-infliximab and infliximab levels in patient serum","volume":"106","author":"Wang","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"key20161111091621264_ref1-bib131","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jim.2012.06.002","article-title":"Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum","volume":"382","author":"Wang","year":"2012","journal-title":"J Immunol Methods"},{"key":"key20161111091621264_ref1-bib132","first-page":"100","article-title":"Clinical utility of measuring adalimumab trough levels and antibodies to adalimumab in patients with inflammatory bowel diseases","volume":"28","author":"Ward","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"key20161111091621264_ref1-bib133","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/j.1365-2036.2008.03828.x","article-title":"Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn\u2019s disease","volume":"28","author":"West","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"key20161111091621264_ref1-bib134","doi-asserted-by":"publisher","first-page":"S788","DOI":"10.1016\/S0016-5085(12)63061-3","article-title":"The questionable value of infliximab trough levels during prolonged maintenance therapy","volume":"142","author":"Yanai","year":"2012","journal-title":"Gastroenterology"},{"key":"key20161111091621264_ref1-bib135","doi-asserted-by":"publisher","first-page":"S774","DOI":"10.1016\/S0016-5085(13)62863-2","article-title":"TU1147 serum adalimumab levels and antibodies correlate with endoscopic intestinal inflammation and inflammatory markers in patients with inflammatory bowel disease","volume":"144","author":"Yarur","year":"2013","journal-title":"Gastroenterology"},{"key":"key20161111091621264_ref1-bib136","doi-asserted-by":"publisher","first-page":"e291","DOI":"10.1515\/cclm-2013-0570","article-title":"Reply to Ruiz-Arguello et al.: comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels","volume":"51","author":"Rispens","year":"2013","journal-title":"Clin Chem Lab Med"},{"key":"key20161111091621264_ref1-bib137","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1136\/annrheumdis-2012-eular.3425","article-title":"Clinical impact of immunogenicity of infliximab, adalimumab and etanercept: a systematic review of the literature with a meta-analysis (SAT0479)","volume":"71","author":"Garces","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key20161111091621264_ref1-bib138","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/1756283X13479826","article-title":"Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response","volume":"6","author":"Lichtenstein","year":"2013","journal-title":"Therap Adv Gastroenterol"},{"key":"key20161111091621264_ref1-bib139","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/ajg.2011.103","article-title":"Assessing response and loss of response to biological therapies in IBD","volume":"106","author":"Yanai","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"key20161111091621264_ref1-bib140","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1136\/gutjnl-2014-307883","article-title":"The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn\u2019s disease","volume":"64","author":"Vande Casteele","year":"2014","journal-title":"Gut"},{"key":"key20161111091621264_ref1-bib141","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0","author":"Higgins","year":"2011"},{"key":"key20161111091621264_ref1-bib142","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1136\/gut.2009.183095","article-title":"Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis","volume":"59","author":"Seow","year":"2010","journal-title":"Gut"},{"key":"key20161111091621264_ref1-bib143","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198509844.001.0001","volume-title":"The Statistical Evaluation of Medical Tests for Classification and Prediction","author":"Pepe","year":"2003"},{"key":"key20161111091621264_ref1-bib144","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/biostatistics\/kxl004","article-title":"A unification of models for meta-analysis of diagnostic accuracy studies","volume":"8","author":"Harbord","year":"2007","journal-title":"Biostatistics"},{"key":"key20161111091621264_ref1-bib145","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"key20161111091621264_ref1-bib146","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn\u2019s disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med"},{"key":"key20161111091621264_ref1-bib147","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/00005176-200405000-00008","article-title":"Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab","volume":"38","author":"Miele","year":"2004","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"key20161111091621264_ref1-bib148","doi-asserted-by":"crossref","first-page":"S774","DOI":"10.1016\/S0016-5085(11)63212-5","article-title":"Can measurements of anti-infliximab antibodies predict acute severe infusion reactions to infliximab?","volume":"140","author":"Steenholdt","year":"2011","journal-title":"Gastroenterology"},{"issue":"36","key":"key20161111091621264_ref1-bib149","doi-asserted-by":"publisher","DOI":"10.3310\/hta8360","article-title":"Review of guidelines for good practice in decision-analytic modelling in health technology assessment","volume":"8","author":"Philips","year":"2004","journal-title":"Health Technol Assess"},{"key":"key20161111091621264_ref1-bib150","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0016-5085(99)70549-4","article-title":"Clinical course and costs of care for Crohn\u2019s disease: Markov model analysis of a population-based cohort","volume":"117","author":"Silverstein","year":"1999","journal-title":"Gastroenterology"},{"key":"key20161111091621264_ref1-bib151","volume-title":"British National Formulary","author":"Joint Formulary Committee","year":"2007","edition":"53 ed."},{"key":"key20161111091621264_ref1-bib152","volume-title":"British National Formulary","author":"Joint Formulary Committee","year":"2008","edition":"55 ed."},{"key":"key20161111091621264_ref1-bib153","volume-title":"NHS Reference Costs 2005 to 2006","author":"Department of Health","year":"2006"},{"key":"key20161111091621264_ref1-bib154","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.crohns.2011.07.007","article-title":"Canadian cost\u2013utility analysis of initiation and maintenance treatment with anti-TNF-alpha drugs for refractory Crohn\u2019s disease","volume":"6","author":"Blackhouse","year":"2012","journal-title":"J Crohns Colitis"},{"key":"key20161111091621264_ref1-bib155","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1365-2036.2009.04033.x","article-title":"Cost-effectiveness of biological therapy for Crohn\u2019s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data","volume":"30","author":"Bodger","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"key20161111091621264_ref1-bib156","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1111\/j.1365-2036.2007.03548.x","article-title":"Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn\u2019s disease: a cost-effectiveness analysis","volume":"26","author":"Kaplan","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"key20161111091621264_ref1-bib157","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.cgh.2012.12.035","article-title":"A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn\u2019s disease who lose responsiveness to infliximab","volume":"11","author":"Velayos","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key20161111091621264_ref1-bib158","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1017\/S0266462313000160","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement","volume":"29","author":"Husereau","year":"2013","journal-title":"Int J Technol Assess Health Care"},{"key":"key20161111091621264_ref1-bib159","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/MIB.0000000000000225","article-title":"Factors associated with durable response to infliximab in Crohn\u2019s disease 5 years and beyond: a multicenter international cohort","volume":"21","author":"Juillerat","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"key20161111091621264_ref1-bib160","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.crohns.2013.04.007","article-title":"Determinants of health-related quality of life in Crohn\u2019s disease: a systematic review and meta-analysis","volume":"8","author":"van der Have","year":"2014","journal-title":"J Crohns Colitis"},{"key":"key20161111091621264_ref1-bib161","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/j.crohns.2014.05.007","article-title":"Crohn\u2019s disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study","volume":"8","author":"Ma","year":"2014","journal-title":"J Crohns Colitis"},{"key":"key20161111091621264_ref1-bib162","doi-asserted-by":"publisher","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"key":"key20161111091621264_ref1-bib163","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1053\/j.gastro.2011.03.050","article-title":"Outcomes of patients with Crohn\u2019s disease improved from 1988 to 2008 and were associated with increased specialist care","volume":"141","author":"Nguyen","year":"2011","journal-title":"Gastroenterology"},{"key":"key20161111091621264_ref1-bib164","doi-asserted-by":"publisher","first-page":"CD010233","DOI":"10.1002\/14651858.cd010233.pub2","article-title":"Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn\u2019s disease","volume":"8","author":"Gordon","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"key20161111091621264_ref1-bib165","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn\u2019s disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"key":"key20161111091621264_ref1-bib166","volume-title":"British National Formulary","author":"Joint Formulary Committee","year":"2013"},{"key":"key20161111091621264_ref1-bib167","volume-title":"NHS Reference Costs 2013 to 2014","author":"Department of Health","year":"2014"},{"key":"key20161111091621264_ref1-bib168","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1586\/14737167.2014.957682","article-title":"Biological therapies in Crohn\u2019s disease: are they cost-effective? A critical appraisal of model-based analyses","volume":"14","author":"Marchetti","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"key20161111091621264_ref1-bib169","volume-title":"National Life Tables, United Kingdom, 1980\u201382 to 2011\u201313","author":"Office for National Statistics","year":"2014"},{"key":"key20161111091621264_ref1-bib170","volume-title":"Unit Costs of Health and Social Care 2014","author":"Curtis","year":"2014"},{"key":"key20161111091621264_ref1-bib171","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4236\/health.2014.61017","volume":"6","author":"Saito","year":"2014","journal-title":"Health (NY)"},{"key":"key20161111091621264_ref1-bib172","doi-asserted-by":"crossref","first-page":"S634","DOI":"10.14309\/00000434-201210001-01572","article-title":"Clinical implications of measuring infliximab levels and human anti-chimeric antibodies in patients with inflammatory bowel disease","volume":"107","author":"Rai","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"key20161111091621264_ref1-bib173","doi-asserted-by":"crossref","first-page":"S641","DOI":"10.14309\/00000434-201210001-01589","article-title":"The use of human anti-chimeric antibody (HACA) and infliximab levels in the management of inflammatory bowel disease","volume":"107","author":"Armbruster","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"key20161111091621264_ref1-bib174","doi-asserted-by":"publisher","first-page":"S-242","DOI":"10.1016\/S0016-5085(14)60853-2","article-title":"Infliximab and antibody to infliximab concentrations in 7,613 patients shows indication for testing, association with loss of response and provides new insights into binding characteristics of anti-drug antibodies","volume":"146","author":"Vande Casteele","year":"2014","journal-title":"Gastroenterology"},{"key":"key20161111091621264_ref1-bib175","doi-asserted-by":"publisher","first-page":"S-423","DOI":"10.1016\/S0016-5085(13)61559-0","article-title":"A multi-center observational study in community gastroenterology practices evaluating the clinical usage of testing for serum levels of infliximab and antibodies to infliximab","volume":"144","author":"Wolf","year":"2013","journal-title":"Gastroenterology"},{"key":"key20161111091621264_ref1-bib176","doi-asserted-by":"publisher","first-page":"S531","DOI":"10.1016\/S0016-5085(13)61975-7","article-title":"Clinical outcome of pediatric IBD patients after measurement of infliximab drug and anti-drug antibody levels","volume":"144","author":"Turon","year":"2013","journal-title":"Gastroenterology"},{"key":"key20161111091621264_ref1-bib177","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1136\/flgastro-2014-100441","article-title":"Mapping of Crohn\u2019s disease outcomes to faecal calprotectin levels in patients maintained on biologic therapy","volume":"5","author":"Turvill","year":"2014","journal-title":"Frontline Gastroenterol"},{"key":"key20161111091621264_ref1-bib178","volume-title":"Infliximab, Adalimumab and Golimumab for Treating Moderately to Severely Active Ulcerative Colitis after the Failure of Conventional Therapy. NICE technology appraisal guidance [TA329]","author":"NICE","year":"2015"},{"key":"key20161111091621264_ref1-bib179","doi-asserted-by":"publisher","first-page":"S-780","DOI":"10.1016\/S0016-5085(13)62883-8","article-title":"Infliximab is more immunogenic and reaches lower trough levels in ulcerative colitis patients compared to Crohn\u2019s disease patients","volume":"144","author":"Bar-yoseph","year":"2013","journal-title":"Gastroenterology"},{"key":"key20161111091621264_ref1-bib180","doi-asserted-by":"publisher","first-page":"S143","DOI":"10.1016\/S0016-5085(16)30583-2","article-title":"692 Drug-level based dosing versus symptom-based dose adaptation in patients with crohn's disease: a prospective, randomized multicenter study (TAILORIX)","volume":"150","author":"D\u2019Haens","year":"2016","journal-title":"Gastroenterology"},{"key":"key20161111091621264_ref1-bib181","volume-title":"OP029 Drug-Concentration Versus Symptom-Driven Dose Adaptation of Infliximab in Patients with Active Crohn\u2019s Disease: A Prospective, Randomised, Multicentre Trial (Tailorix)","author":"D\u2019Haens","year":"2016"},{"key":"key20161111091621264_ref1-bib182","doi-asserted-by":"publisher","first-page":"S-860","DOI":"10.1016\/S0016-5085(15)32913-9","article-title":"TU1325 therapeutic cut-off of infliximab in patients with inflammatory bowel diseases","volume":"148","author":"Nagore","year":"2015","journal-title":"Gastroenterology"},{"key":"key20161111091621264_ref1-bib183","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/j.crohns.2014.07.010","article-title":"Hospitalisation, surgical and medical recurrence rates in inflammatory bowel disease 2003\u20132011\u2009\u2013\u2009a Danish population-based cohort study","volume":"8","author":"Vester-Andersen","year":"2014","journal-title":"J Crohns Colitis"},{"key":"key20161111091621264_ref1-bib184","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1136\/gut.2009.202101","article-title":"Natural history of Crohn\u2019s disease in a population-based cohort from Cardiff (1986\u20132003): a study of changes in medical treatment and surgical resection rates","volume":"59","author":"Ramadas","year":"2010","journal-title":"Gut"},{"key":"key20161111091621264_ref1-bib185","doi-asserted-by":"publisher","first-page":"e623","DOI":"10.1016\/j.crohns.2013.04.020","article-title":"Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn\u2019s disease: an open-label pilot study","volume":"7","author":"Armuzzi","year":"2013","journal-title":"J Crohns Colitis"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta20830\/hta20830.xml","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2002549","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta20830\/hta20830.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2003464","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T12:13:49Z","timestamp":1718885629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta20830\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":185,"journal-issue":{"issue":"83","published-online":{"date-parts":[[2016,11]]}},"alternative-id":["10.3310\/hta20830"],"URL":"https:\/\/doi.org\/10.3310\/hta20830","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"}]}}